{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T02:26:11Z","timestamp":1777170371954,"version":"3.51.4"},"reference-count":117,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T00:00:00Z","timestamp":1650326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacy"],"abstract":"<jats:p>The opioid epidemic is an ongoing public health crisis, and the United States health system is overwhelmed with increasing numbers of opioid-related overdoses. Methocinnamox (MCAM) is a novel mu opioid receptor antagonist with an extended duration of action. MCAM has potential to reduce the burden of the opioid epidemic by being used as an overdose rescue treatment and a long-term treatment for opioid use disorder (OUD). The currently available treatments for OUD include naloxone, naltrexone, and methadone. These treatments have certain limitations, which include short duration of action, patient non-compliance, and diversion. A narrative review was conducted using PubMed and Google Scholar databases covering the history of the opioid epidemic, pain receptors, current OUD treatments and the novel drug MCAM. MCAM could potentially be used as both a rescue and long-term treatment for opioid misuse. This is due to its pseudo-irreversible antagonism of the mu opioid receptor, abnormally long duration of action of nearly two weeks, and the possibility of using kappa or delta opioid receptor agonists for pain management during OUD treatment. MCAM\u2019s novel pharmacokinetic and pharmacodynamic properties open a new avenue for treating opioid misuse.<\/jats:p>","DOI":"10.3390\/pharmacy10030048","type":"journal-article","created":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:22:43Z","timestamp":1650414163000},"page":"48","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The Potential of Methocinnamox as a Future Treatment for Opioid Use Disorder: A Narrative Review"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1434-6956","authenticated-orcid":false,"given":"Colleen G.","family":"Jordan","sequence":"first","affiliation":[{"name":"Department of Medical Education, Geisinger Commonwealth School of Medicine, Scranton, PA 18509, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1845-7765","authenticated-orcid":false,"given":"Amy L.","family":"Kennalley","sequence":"additional","affiliation":[{"name":"Department of Medical Education, Geisinger Commonwealth School of Medicine, Scranton, PA 18509, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6910-0822","authenticated-orcid":false,"given":"Alivia L.","family":"Roberts","sequence":"additional","affiliation":[{"name":"Department of Medical Education, Geisinger Commonwealth School of Medicine, Scranton, PA 18509, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9891-6364","authenticated-orcid":false,"given":"Kaitlyn M.","family":"Nemes","sequence":"additional","affiliation":[{"name":"Department of Medical Education, Geisinger Commonwealth School of Medicine, Scranton, PA 18509, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tenzing","family":"Dolma","sequence":"additional","affiliation":[{"name":"Department of Medical Education, Geisinger Commonwealth School of Medicine, Scranton, PA 18509, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2295-445X","authenticated-orcid":false,"given":"Brian J.","family":"Piper","sequence":"additional","affiliation":[{"name":"Department of Medical Education, Geisinger Commonwealth School of Medicine, Scranton, PA 18509, USA"},{"name":"Center for Pharmacy Innovation and Outcomes, Forty Fort, PA 18704, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,19]]},"reference":[{"key":"ref_1","unstructured":"(2022, January 23). More than a Million Americans Have Died from Overdoses during the Opioid Epidemic. Available online: https:\/\/www.npr.org\/2021\/12\/30\/1069062738\/more-than-a-million-americans-have-died-from-overdoses-during-the-opioid-epidemi."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1124\/jpet.119.259408","article-title":"The Opioid Crisis and the Future of Addiction and Pain Therapeutics","volume":"371","author":"Coussens","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1177\/1529100619860513","article-title":"A Neurobehavioral Approach to Addiction: Implications for the Opioid Epidemic and the Psychology of Addiction","volume":"20","author":"Bechara","year":"2019","journal-title":"Psychol. Sci. Public Interest"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1124\/jpet.119.258566","article-title":"Noradrenergic Mechanisms in Fentanyl-Mediated Rapid Death Explain Failure of Naloxone in the Opioid Crisis","volume":"371","author":"Torralva","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Hoffman, K.A., Ponce Terashima, J., and McCarty, D. (2019). Opioid Use Disorder and Treatment: Challenges and Opportunities. BMC Health Serv. Res., 19.","DOI":"10.1186\/s12913-019-4751-4"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"E587","DOI":"10.1208\/aapsj070360","article-title":"Mu Opioid Receptor Regulation and Opiate Responsiveness","volume":"7","author":"Raehal","year":"2005","journal-title":"AAPS J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S0165-6147(98)01169-9","article-title":"Mu-Opposing Actions of the Kappa-Opioid Receptor","volume":"19","author":"Pan","year":"1998","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1080\/10826084.2019.1653324","article-title":"Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care: An in-Depth Qualitative Survey on Buprenorphine and Extended-Release Naltrexone","volume":"54","author":"Tofighi","year":"2019","journal-title":"Subst. Use Misuse"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ejphar.2018.08.004","article-title":"On the Front Lines of the Opioid Epidemic: Rescue by Naloxone","volume":"835","author":"Skolnick","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2217\/pmt-2017-0060","article-title":"Pharmacokinetic Properties of Intranasal and Injectable Formulations of Naloxone for Community Use: A Systematic Review","volume":"8","author":"Ryan","year":"2018","journal-title":"Pain Manag."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"107804","DOI":"10.1016\/j.drugalcdep.2019.107804","article-title":"Changes in Fentanyl Demand Following Naltrexone, Morphine, and Buprenorphine in Male Rats","volume":"207","author":"Hammerslag","year":"2020","journal-title":"Drug Alcohol Depend."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13011-019-0195-4","article-title":"Higher Doses of Naloxone Are Needed in the Synthetic Opioid Era","volume":"14","author":"Moss","year":"2019","journal-title":"Subst. Abuse Treat. Prev. Policy"},{"key":"ref_13","unstructured":"(2022, January 23). DEA: \u201cLazarus Parties\u201d or \u201cNarcan Parties\u201d are Real. Available online: https:\/\/foxsanantonio.com\/news\/yami-investigates\/dea-lazarus-parties-or-narcan-parties-are-real."},{"key":"ref_14","first-page":"CD001333","article-title":"Oral Naltrexone Maintenance Treatment for Opioid Dependence","volume":"4","author":"Minozzi","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_15","first-page":"CD002207","article-title":"Buprenorphine Maintenance versus Placebo or Methadone Maintenance for Opioid Dependence","volume":"3","author":"Mattick","year":"2004","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"106105","DOI":"10.1016\/j.ypmed.2020.106105","article-title":"Leveraging Black-Market Street Buprenorphine Pricing to Increase Capacity to Treat Opioid Addiction, 2010\u20132018","volume":"137","author":"Hswen","year":"2020","journal-title":"Prev. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"109924","DOI":"10.1016\/j.forsciint.2019.109924","article-title":"Increasing Heroin, Cocaine, and Buprenorphine Arrests Reported to the Maine Diversion Alert Program","volume":"303","author":"Simpson","year":"2019","journal-title":"Forensic Sci. Int."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality Risk during and after Opioid Substitution Treatment: Systematic Review and Meta-Analysis of Cohort Studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1038\/s41386-020-0698-8","article-title":"Effects of Acute and Repeated Treatment with Methocinnamox, a Mu Opioid Receptor Antagonist, on Fentanyl Self-Administration in Rhesus Monkeys","volume":"45","author":"Maguire","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"ref_20","first-page":"933","article-title":"Methocinnamox Is a Potent, Long-Lasting, and Selective Antagonist of Morphine-Mediated Antinociception in the Mouse: Comparison with Clocinnamox, Beta-Funaltrexamine, and Beta-Chlornaltrexamine","volume":"294","author":"Broadbear","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1096\/fasebj.2020.34.s1.05397","article-title":"Methocinnamox Produces Sustained Antagonism of the Antinociceptive Effects of Morphine and Persistent Decreases in [3H]DAMGO Binding to \u03bc Opioid Receptors in Rat Cortex","volume":"34","author":"Gerak","year":"2020","journal-title":"FASEB J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1124\/jpet.118.252353","article-title":"Long-Lasting Effects of Methocinnamox on Opioid Self-Administration in Rhesus Monkeys","volume":"368","author":"Maguire","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"498.8","DOI":"10.1096\/fasebj.2019.33.1_supplement.498.8","article-title":"Methocinnamox (MCAM) Is a Selective, Long Acting Antagonist at Mu Opioid Receptors In Vitro","volume":"33","author":"Zamora","year":"2019","journal-title":"FASEB J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1038\/s41386-020-0717-9","article-title":"The Lasting Impact of Methocinnamox on Opioid Self-Administration","volume":"45","author":"Townsend","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1096\/fasebj.2020.34.s1.00750","article-title":"Long-Term Antagonism of Mu Opioid Receptors by Methocinnamox (MCAM) without Adverse Effects on Memory","volume":"34","author":"Minervini","year":"2020","journal-title":"FASEB J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1053\/j.semperi.2019.01.001","article-title":"The United States Opioid Epidemic","volume":"43","author":"Lyden","year":"2019","journal-title":"Semin. Perinatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMp1508818","article-title":"Preventing and Treating Narcotic Addiction\u2014A Century of Federal Drug Control","volume":"373","author":"Courtwright","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.bja.2017.11.098","article-title":"\u201cPain as the Fifth Vital Sign\u201d and Dependence on the \u201cNumerical Pain Scale\u201d Is Being Abandoned in the US: Why?","volume":"120","author":"Levy","year":"2018","journal-title":"Br. J. Anaesth."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2105\/AJPH.2007.131714","article-title":"The Promotion and Marketing of OxyContin: Commercial Triumph, Public Health Tragedy","volume":"99","year":"2009","journal-title":"Am. J. Public Health"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40122-018-0097-6","article-title":"A Brief History of the Opioid Epidemic and Strategies for Pain Medicine","volume":"7","author":"Jones","year":"2018","journal-title":"Pain Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/0033354919887741","article-title":"The Emerging Role of Toxic Adulterants in Street Drugs in the US Illicit Opioid Crisis","volume":"135","author":"Singh","year":"2020","journal-title":"Public Health Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"349","DOI":"10.15585\/mmwr.mm6712a1","article-title":"Overdose Deaths Involving Opioids, Cocaine, and Psychostimulants\u2014United States, 2015\u20132016","volume":"67","author":"Seth","year":"2018","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e15425","DOI":"10.1097\/MD.0000000000015425","article-title":"Current Perspectives on the Opioid Crisis in the US Healthcare System: A Comprehensive Literature Review","volume":"98","author":"Stoicea","year":"2019","journal-title":"Medicine"},{"key":"ref_34","first-page":"S200","article-title":"Introduction to the Opioid Epidemic: The Economic Burden on the Healthcare System and Impact on Quality of Life","volume":"24","author":"Hagemeier","year":"2018","journal-title":"Am. J. Manag. Care"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/pds.4984","article-title":"Rise and Regional Disparities in Buprenorphine Utilization in the United States","volume":"29","author":"Podd","year":"2020","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_36","first-page":"10600280211028262","article-title":"Pronounced Regional Disparities in United States Methadone Distribution","volume":"56","author":"Furst","year":"2021","journal-title":"Ann. Pharmacother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1111\/add.14634","article-title":"The Impact of Expanded Medicaid Eligibility on Access to Naloxone","volume":"114","author":"Frank","year":"2019","journal-title":"Addiction"},{"key":"ref_38","unstructured":"(2022, January 24). Drug Overdose Deaths in the U.S. Top 100,000 Annually|cdc.gov, Available online: https:\/\/www.cdc.gov\/nchs\/pressroom\/nchs_press_releases\/2021\/20211117.htm."},{"key":"ref_39","unstructured":"(2022, January 23). Understanding the Epidemic|CDC\u2019s Response to the Opioid Overdose Epidemic|cdc.gov, Available online: https:\/\/www.cdc.gov\/opioids\/basics\/epidemic.html."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41398-019-0625-0","article-title":"The Rising Crisis of Illicit Fentanyl Use, Overdose, and Potential Therapeutic Strategies","volume":"9","author":"Han","year":"2019","journal-title":"Transl. Psychiatry"},{"key":"ref_41","first-page":"478","article-title":"Seeking Solutions to the Opioid Crisis","volume":"42","author":"McIver","year":"2017","journal-title":"P.T."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"24S","DOI":"10.1177\/0033354918793627","article-title":"A Public Health Strategy for the Opioid Crisis","volume":"133","author":"Saloner","year":"2018","journal-title":"Public Health Rep."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1007\/s11606-020-06436-3","article-title":"COVID-19 Adaptations in the Care of Patients with Opioid Use Disorder: A Survey of California Primary Care Clinics","volume":"36","author":"Caton","year":"2021","journal-title":"J. Gen. Intern. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2050324520940428","article-title":"Exploring the Impact of the Opioid Epidemic in Black and Hispanic Communities in the United States","volume":"6","author":"Drake","year":"2020","journal-title":"Drug Sci. Policy Law"},{"key":"ref_45","unstructured":"(2022, April 04). As the Pandemic Ushered in Isolation and Financial Hardship, Overdose Deaths Reached New Heights. Available online: https:\/\/www.statnews.com\/2021\/02\/16\/as-pandemic-ushered-in-isolation-financial-hardship-overdose-deaths-reached-new-heights\/."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1146\/annurev-publhealth-031914-122957","article-title":"The Prescription Opioid and Heroin Crisis: A Public Health Approach to an Epidemic of Addiction","volume":"36","author":"Kolodny","year":"2015","journal-title":"Annu. Rev. Public Health"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/cpt.2098","article-title":"Countermeasures for Preventing and Treating Opioid Overdose","volume":"109","author":"France","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41380-020-0661-4","article-title":"The Changing Opioid Crisis: Development, Challenges and Opportunities","volume":"26","author":"Volkow","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"498.10","DOI":"10.1096\/fasebj.2019.33.1_supplement.498.10","article-title":"Methocinnamox: Sustained Antagonism of the Antinociceptive Effects of Morphine and Not Spiradoline in Rats","volume":"33","author":"Gerak","year":"2019","journal-title":"FASEB J."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"498.9","DOI":"10.1096\/fasebj.2019.33.1_supplement.498.9","article-title":"Methocinnamox (MCAM) Is an Effective Long-Term Antagonist of Peripheral Mu, but Not Kappa or Delta Opioid Receptors In Vivo","volume":"33","author":"Jennings","year":"2019","journal-title":"FASEB J."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/B978-0-12-420118-7.00010-X","article-title":"Mixed \u03ba\/\u03bc partial opioid agonists as potential treatments for cocaine dependence","volume":"69","author":"Bidlack","year":"2014","journal-title":"Adv. Pharmacol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nature19112","article-title":"Structure-Based Discovery of Opioid Analgesics with Reduced Side Effects","volume":"537","author":"Manglik","year":"2016","journal-title":"Nature"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"16346","DOI":"10.1073\/pnas.1918264117","article-title":"Mechanism of \u03b2-Arrestin Recruitment by the \u03bc-Opioid G Protein-Coupled Receptor","volume":"117","author":"Mafi","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Gibula-Tarlowska, E., and Kotlinska, J.H. (2020). Crosstalk between Opioid and Anti-Opioid Systems: An Overview and Its Possible Therapeutic Significance. Biomolecules, 10.","DOI":"10.3390\/biom10101376"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1097\/ALN.0b013e318238bba6","article-title":"Molecular Mechanisms of Opioid Receptor-Dependent Signaling and Behavior","volume":"115","author":"Bruchas","year":"2011","journal-title":"Anesthesiology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1146\/annurev-neuro-080317-061522","article-title":"Endogenous and Exogenous Opioids in Pain","volume":"41","author":"Corder","year":"2018","journal-title":"Annu. Rev. Neurosci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"26218","DOI":"10.1073\/pnas.2013364117","article-title":"Exploring the Activation Pathway and Gi-Coupling Specificity of the \u03bc-Opioid Receptor","volume":"117","author":"Mondal","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1007\/s00018-008-8006-5","article-title":"G Protein \u0392\u03b3 Subunits: Central Mediators of G Protein-Coupled Receptor Signaling","volume":"65","author":"Smrcka","year":"2008","journal-title":"Cell Mol. Life Sci."},{"key":"ref_59","unstructured":"Shenoy, S.S., and Lui, F. (2022, January 23). Biochemistry, Endogenous Opioids, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK532899\/."},{"key":"ref_60","unstructured":"National Academies of Sciences, Engineering and Medicine, Health and Medicine Division, Board on Health Sciences Policy, Committee on Medication-Assisted Treatment for Opioid Use Disorder, Mancher, M., and Leshner, A.I. (2022, January 23). The Effectiveness of Medication-Based Treatment for Opioid Use Disorder, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK541393\/."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Lipi\u0144ski, P.F.J., Kosson, P., Matali\u0144ska, J., Roszkowski, P., Czarnocki, Z., Jaro\u0144czyk, M., Misicka, A., Dobrowolski, J.C., and Sadlej, J. (2019). Fentanyl Family at the Mu-Opioid Receptor: Uniform Assessment of Binding and Computational Analysis. Molecules, 24.","DOI":"10.3390\/molecules24040740"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1007\/s00213-018-4920-x","article-title":"Interactions between kappa and mu opioid receptor agonists: Effects of the ratio of drugs in mixtures","volume":"235","author":"Minervini","year":"2018","journal-title":"Psychopharmacology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1097\/j.pain.0000000000001458","article-title":"Kappa Opioid Signaling in the Central Nucleus of the Amygdala Promotes Disinhibition and Aversiveness of Chronic Neuropathic Pain","volume":"160","author":"Navratilova","year":"2019","journal-title":"Pain"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"100277","DOI":"10.1016\/j.jbc.2021.100277","article-title":"Switching of Delta Opioid Receptor Subtypes in Central Amygdala Microcircuits Is Associated with Anxiety States in Pain","volume":"296","author":"Zhou","year":"2021","journal-title":"J. Biol. Chem."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Al-Eitan, L.N., Rababa\u2019h, D.M., and Alghamdi, M.A. (2021). Genetic Susceptibility of Opioid Receptor Genes Polymorphism to Drug Addiction: A Candidate-Gene Association Study. BMC Psychiatry, 21.","DOI":"10.1186\/s12888-020-03006-z"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1523\/JNEUROSCI.0274-19.2019","article-title":"Kappa Opioid Receptors Drive a Tonic Aversive Component of Chronic Pain","volume":"39","author":"Liu","year":"2019","journal-title":"J. Neurosci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.neuron.2019.02.029","article-title":"Pain-Induced Negative Affect Is Mediated via Recruitment of The Nucleus Accumbens Kappa Opioid System","volume":"102","author":"Massaly","year":"2019","journal-title":"Neuron"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1037\/a0013628","article-title":"Opioids and the Treatment of Chronic Pain: Controversies, Current Status, and Future Directions","volume":"16","author":"Rosenblum","year":"2008","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s40263-019-00660-0","article-title":"Opioid-Induced Tolerance and Hyperalgesia","volume":"33","author":"Mercadante","year":"2019","journal-title":"CNS Drugs"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1151\/spp021113","article-title":"The Neurobiology of Opioid Dependence: Implications for Treatment","volume":"1","author":"Kosten","year":"2002","journal-title":"Sci. Pract. Perspect."},{"key":"ref_71","first-page":"200","article-title":"Primary Care Management of Opioid Use Disorders: Abstinence, Methadone, or Buprenorphine-Naloxone?","volume":"63","author":"Srivastava","year":"2017","journal-title":"Can. Fam. Physician"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s40263-018-0560-2","article-title":"Buprenorphine\/Naloxone (Zubsolv\u00ae): A Review in Opioid Dependence","volume":"32","author":"Heo","year":"2018","journal-title":"CNS Drugs"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1176\/appi.ajp.2018.17070732","article-title":"A Randomized Trial Comparing Extended-Release Injectable Suspension and Oral Naltrexone, Both Combined With Behavioral Therapy, for the Treatment of Opioid Use Disorder","volume":"176","author":"Sullivan","year":"2019","journal-title":"Am. J. Psychiatry."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1097\/ALN.0000000000000170","article-title":"Buprenorphine-Naloxone Therapy in Pain Management","volume":"120","author":"Chen","year":"2014","journal-title":"Anesthesiology"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/10408363.2011.620601","article-title":"Methadone: A Review of Drug-Drug and Pathophysiological Interactions","volume":"48","author":"Kapur","year":"2011","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/add.14180","article-title":"Extended-Release Injectable Naltrexone for Opioid Use Disorder: A Systematic Review","volume":"113","author":"Jarvis","year":"2018","journal-title":"Addiction"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jsat.2017.07.001","article-title":"Injectable Naltrexone, Oral Naltrexone, and Buprenorphine Utilization and Discontinuation among Individuals Treated for Opioid Use Disorder in a United States Commercially Insured Population","volume":"85","author":"Morgan","year":"2018","journal-title":"J. Subst. Abuse. Treat."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s13181-015-0512-x","article-title":"Naltrexone: Not Just for Opioids Anymore","volume":"12","author":"Sudakin","year":"2016","journal-title":"J. Med. Toxicol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0025-6196(11)60846-X","article-title":"Internet Sex Addiction Treated with Naltrexone","volume":"83","author":"Bostwick","year":"2008","journal-title":"Mayo Clin. Proc."},{"key":"ref_80","first-page":"e12892","article-title":"Use of Low-Dose Naltrexone in the Treatment of Severe Hailey-Hailey Disease: One Case Report","volume":"32","year":"2019","journal-title":"Dermatol. Ther."},{"key":"ref_81","first-page":"CD003086","article-title":"Opioid Antagonists for Smoking Cessation","volume":"6","author":"David","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study","volume":"169","author":"Larochelle","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.phrs.2004.05.002","article-title":"Methadone--Metabolism, Pharmacokinetics and Interactions","volume":"50","author":"Ferrari","year":"2004","journal-title":"Pharmacol. Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4103\/0976-3147.91934","article-title":"Buprenorphine vs Methadone Treatment: A Review of Evidence in Both Developed and Developing Worlds","volume":"3","author":"Whelan","year":"2012","journal-title":"J. Neurosci. Rural Pract."},{"key":"ref_85","first-page":"29","article-title":"Buprenorphine: A (relatively) new treatment for opioid dependence","volume":"2","author":"Welsh","year":"2005","journal-title":"Psychiatry"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/ewjm.172.1.43","article-title":"Use of Methadone","volume":"172","author":"Anderson","year":"2000","journal-title":"West. J. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1124\/jpet.109.152678","article-title":"The relative potency of inverse opioid agonists and a neutral opioid antagonist in precipitated withdrawal and antagonism of analgesia and toxicity","volume":"330","author":"Sirohi","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/2042098617744161","article-title":"Naloxone Dosage for Opioid Reversal: Current Evidence and Clinical Implications","volume":"9","author":"Galinkin","year":"2018","journal-title":"Ther. Adv. Drug Saf."},{"key":"ref_89","unstructured":"Katzung, B.G. (2017). Opioid Agonists & Antagonists. Basic & Clinical Pharmacology, McGraw-Hill Education. Available online: https:\/\/accessmedicine.mhmedical.com\/content.aspx?bookid=2249&sectionid=175220393."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/306264a0","article-title":"Placebo and Naloxone Can Alter Post-Surgical Pain by Separate Mechanisms","volume":"306","author":"Gracely","year":"1983","journal-title":"Nature"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.neuron.2009.07.014","article-title":"Activation of the Opioidergic Descending Pain Control System Underlies Placebo Analgesia","volume":"63","author":"Eippert","year":"2009","journal-title":"Neuron"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.clinthera.2019.07.003","article-title":"Naltrexone Treatment for Pregnant Women With Opioid Use Disorder Compared With Matched Buprenorphine Control Subjects","volume":"41","author":"Wachman","year":"2019","journal-title":"Clin. Ther."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/phar.1958","article-title":"Methadone, Buprenorphine, and Naltrexone for the Treatment of Opioid Use Disorder in Pregnant Women","volume":"37","author":"Tran","year":"2017","journal-title":"Pharmacotherapy"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S0140-6736(11)60358-9","article-title":"Injectable Extended-Release Naltrexone for Opioid Dependence: A Double-Blind, Placebo-Controlled, Multicentre Randomised Trial","volume":"377","author":"Krupitsky","year":"2011","journal-title":"Lancet"},{"key":"ref_95","unstructured":"(2022, January 26). Naloxone, Available online: https:\/\/go.drugbank.com\/drugs\/DB01183."},{"key":"ref_96","unstructured":"(2022, January 26). Naloxone Monograph for Professionals. Available online: https:\/\/www.drugs.com\/monograph\/naloxone.html."},{"key":"ref_97","unstructured":"(2022, January 26). Naltrexone, Available online: https:\/\/go.drugbank.com\/drugs\/DB00704."},{"key":"ref_98","unstructured":"(2022, January 26). Naltrexone Monograph for Professionals. Available online: https:\/\/www.drugs.com\/monograph\/naltrexone.html."},{"key":"ref_99","unstructured":"(2022, January 26). Methadone, Available online: https:\/\/go.drugbank.com\/drugs\/DB00333."},{"key":"ref_100","unstructured":"(2022, January 26). Methadone Monograph for Professionals. Available online: https:\/\/www.drugs.com\/monograph\/methadone.html."},{"key":"ref_101","unstructured":"(2022, April 04). Opioid Prescribing: Methadone Risk Mitigation. Available online: https:\/\/www.apsf.org\/article\/opioid-prescribing-methadone-risk-mitigation\/."},{"key":"ref_102","unstructured":"(2022, January 26). Buprenorphine, Available online: https:\/\/go.drugbank.com\/drugs\/DB00921."},{"key":"ref_103","unstructured":"(2022, January 26). Buprenorphine Monograph for Professionals. Available online: https:\/\/www.drugs.com\/monograph\/buprenorphine.html."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1124\/jpet.120.000387","article-title":"Methocinnamox (MCAM) Reverses and Prevents Fentanyl-Induced Ventilatory Depression in Rats","volume":"377","author":"Jimenez","year":"2021","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1124\/jpet.118.253286","article-title":"Reversal and Prevention of the Respiratory-Depressant Effects of Heroin by the Novel \u03bc-Opioid Receptor Antagonist Methocinnamox in Rhesus Monkeys","volume":"368","author":"Gerak","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"e00887","DOI":"10.1002\/prp2.887","article-title":"Long-term Antagonism and Allosteric Regulation of Mu Opioid Receptors by the Novel Ligand, Methocinnamox","volume":"9","author":"Zamora","year":"2021","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1124\/jpet.119.260331","article-title":"Methocinnamox Produces Long-Lasting Antagonism of the Behavioral Effects of \u00b5-Opioid Receptor Agonists but Not Prolonged Precipitated Withdrawal in Rats","volume":"371","author":"Gerak","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_108","unstructured":"(2022, April 03). Something better than Naloxone. Available online: https:\/\/www.wqad.com\/article\/news\/health\/your-health\/your-health-mcam\/526-cda2622a-69a3-4962-885a-a2185e9507d6."},{"key":"ref_109","unstructured":"(2021, February 14). National Institute on Drug Abuse\u2014A Novel Opioid Receptor Antagonist for Treating Abuse and Overdose, Available online: https:\/\/taggs.hhs.gov\/Detail\/AwardDetail?arg_AwardNum=R01DA048417&arg_ProgOfficeCode=114."},{"key":"ref_110","unstructured":"(2021, February 14). National Institute of Health\u2014Funded Projects, Available online: https:\/\/www.heal.nih.gov\/funding\/awarded."},{"key":"ref_111","unstructured":"Sansom, W. (2022, April 03). Long-lasting treatment drug could slow the opioid crisis. UT Health, Available online: https:\/\/news.uthscsa.edu\/long-lasting-treatment-drug-could-slow-the-opioid-crisis\/."},{"key":"ref_112","unstructured":"(2021, May 15). Compound Summary Methocinnamox, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/46877713."},{"key":"ref_113","first-page":"1","article-title":"Effects of Acute and Repeated Methocinnamox Treatment on Fentanyl Self-administration in Rhesus Monkeys","volume":"34","author":"Maguire","year":"2020","journal-title":"FASEB J."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1007\/s00213-020-05592-y","article-title":"Methocinnamox (MCAM) Antagonizes the Behavioral Suppressant Effects of Morphine without Impairing Delayed Matching-to-Sample Accuracy in Rhesus Monkeys","volume":"237","author":"Minervini","year":"2020","journal-title":"Psychopharmacology"},{"key":"ref_115","first-page":"1","article-title":"Methocinnamox (MCAM) Reverses and Provides Extended Protection from Fentanyl-Induced Respiratory Depression in Awake Unrestrained Rats","volume":"34","author":"Jimenez","year":"2020","journal-title":"FASEB J."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.brainres.2005.07.060","article-title":"Comparison of the Antinociceptive Effect of Acute Morphine in Female and Male Sprague-Dawley Rats Using the Long-Lasting Mu-Antagonist Methocinnamox","volume":"1058","author":"Peckham","year":"2005","journal-title":"Brain Res."},{"key":"ref_117","unstructured":"(2022, April 03). New Drug Blocks the Fatal Effects of Opioids?. Available online: https:\/\/www.wndu.com\/content\/news\/New-drug-blocks-the-fatal-effects-of-opioids-568493251.html."}],"container-title":["Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2226-4787\/10\/3\/48\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:56:34Z","timestamp":1760136994000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2226-4787\/10\/3\/48"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,19]]},"references-count":117,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["pharmacy10030048"],"URL":"https:\/\/doi.org\/10.3390\/pharmacy10030048","relation":{"has-preprint":[{"id-type":"doi","id":"10.20944\/preprints202201.0453.v1","asserted-by":"object"}]},"ISSN":["2226-4787"],"issn-type":[{"value":"2226-4787","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,19]]}}}